NO20090984L - Terapeutiske fremgangsmater for behandling av vaskulaere oyelidelser med DLL4-antagonister - Google Patents
Terapeutiske fremgangsmater for behandling av vaskulaere oyelidelser med DLL4-antagonisterInfo
- Publication number
- NO20090984L NO20090984L NO20090984A NO20090984A NO20090984L NO 20090984 L NO20090984 L NO 20090984L NO 20090984 A NO20090984 A NO 20090984A NO 20090984 A NO20090984 A NO 20090984A NO 20090984 L NO20090984 L NO 20090984L
- Authority
- NO
- Norway
- Prior art keywords
- ischemic
- retinopathy
- coma
- inhibiting
- insufficiency
- Prior art date
Links
- 208000030533 eye disease Diseases 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 102100033553 Delta-like protein 4 Human genes 0.000 title 1
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000002792 vascular Effects 0.000 title 1
- 230000000302 ischemic effect Effects 0.000 abstract 4
- 206010062542 Arterial insufficiency Diseases 0.000 abstract 2
- 206010010071 Coma Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 238000002054 transplantation Methods 0.000 abstract 2
- 208000019553 vascular disease Diseases 0.000 abstract 2
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 abstract 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- 102000005650 Notch Receptors Human genes 0.000 abstract 1
- 108010070047 Notch Receptors Proteins 0.000 abstract 1
- 206010035138 Placental insufficiency Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 230000005744 arteriovenous malformation Effects 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 108700041286 delta Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000037906 ischaemic injury Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 201000003142 neovascular glaucoma Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 210000003462 vein Anatomy 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
En terapeutisk fremgangsmåte for å behandle iskemiske og vaskulære forstyrrelser ved administrering av et middel som er i stand til å inhibere human deltaliknende ligand 4 (Dl 14) aktivitet hos et menneske som har behov for dette. Fortrinnsvis er middelet et anti-Dl 14 antistoff eller -antistoffragment som er i stand til å inhibere bindingen av Dl 14 til en Notch-reseptor. I en utførelsesfonn er den iskemiske eller vaskulære forstyrrelsen iskemisk skade, cerebral iskemi, kardial iskemi, iskemiske tilstander som påvirker lemmer og andre organer eller veva, arteriovenøse misdannelser, sårheling, organ- eller vevstransplantasjon, placenta insuffisiens, arteriell innsnevring og okklusjon, aterosklerose og systemisk eller pulmonær hypertensjon. I en annen utførelsesform er sykdommen som behandles en øyesykdom eller tilstand, slik som prematur retinopati, iskemisk retinopati, retina! vene- eller arterieokklusjon, diabetisk retinopati, koroidal neovasku- larisering, aldersrelatert makula degenerasjon, komeal neovaskularisering, neovaskulært glaukom eller komeal transplantering.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83600306P | 2006-08-07 | 2006-08-07 | |
| PCT/US2007/017546 WO2008019144A2 (en) | 2006-08-07 | 2007-08-07 | Threapeutic methods for treating vascular eye disorders with dll4 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20090984L true NO20090984L (no) | 2009-03-04 |
| NO341857B1 NO341857B1 (no) | 2018-02-12 |
Family
ID=38904599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20090984A NO341857B1 (no) | 2006-08-07 | 2009-03-04 | Anvendelse av en delta-liknende ligand 4 (Dll4)-antagonist for fremstilling av et medikament for å forhindre eller redusere tap av blodkar eller fremme produktiv angiogenese hos et individ som har en iskemisk skade eller vaskulær insuffisiens. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20080181893A1 (no) |
| EP (1) | EP2054082B1 (no) |
| JP (1) | JP5529536B2 (no) |
| KR (1) | KR101497355B1 (no) |
| CN (1) | CN101500605B (no) |
| AU (1) | AU2007281916B2 (no) |
| BR (1) | BRPI0716424B8 (no) |
| CA (1) | CA2660235C (no) |
| CO (1) | CO6150190A2 (no) |
| CR (1) | CR10627A (no) |
| DK (1) | DK2054082T3 (no) |
| ES (1) | ES2398253T3 (no) |
| GT (1) | GT200900029A (no) |
| HR (1) | HRP20130271T1 (no) |
| IL (1) | IL196612A (no) |
| MA (1) | MA30667B1 (no) |
| ME (1) | ME00591A (no) |
| MX (1) | MX2009000674A (no) |
| MY (1) | MY150092A (no) |
| NO (1) | NO341857B1 (no) |
| NZ (1) | NZ574794A (no) |
| PL (1) | PL2054082T3 (no) |
| PT (1) | PT2054082E (no) |
| RS (1) | RS52685B (no) |
| RU (1) | RU2429876C2 (no) |
| SG (1) | SG174033A1 (no) |
| SI (1) | SI2054082T1 (no) |
| SV (1) | SV2009003161A (no) |
| TN (1) | TN2009000036A1 (no) |
| UA (1) | UA95304C2 (no) |
| WO (1) | WO2008019144A2 (no) |
| ZA (1) | ZA200900337B (no) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7750124B2 (en) | 2006-09-29 | 2010-07-06 | Oncomed Pharmaceuticals, Inc. | Anti-human DLL4 antibodies and compositions |
| US20100119526A1 (en) * | 2007-01-26 | 2010-05-13 | Bioinvent International Ab | DLL4 Signaling Inhibitors and Uses Thereof |
| GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| AU2009291747B2 (en) * | 2008-09-10 | 2016-05-26 | Genentech, Inc. | Methods for inhibiting ocular angiogenesis |
| MX2011002837A (es) | 2008-09-19 | 2011-07-29 | Medimmune Llc | Anticuerpos dirigidos al ligando tipo delta 4 (dll4) y usos de los mismos. |
| EP2356270B1 (en) | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| WO2011008641A1 (en) | 2009-07-13 | 2011-01-20 | Beth Israel Deaconess Medical Center, Inc. | Methids of modulating angiogenesis and treatment of angiogenesis-related diseases |
| PE20121647A1 (es) | 2009-08-29 | 2012-12-31 | Abbvie Inc | Proteinas terapeuticas de union a dll4 |
| US20110172398A1 (en) * | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| EP3485908B1 (en) * | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| SG10201501562VA (en) * | 2010-03-02 | 2015-04-29 | Abbvie Inc | Therapeutic dll4 binding proteins |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| HRP20190044T1 (hr) | 2011-09-23 | 2019-02-22 | Oncomed Pharmaceuticals, Inc. | Agensi koji vežu vegf/dll4 i njihove uporabe |
| WO2014062659A2 (en) * | 2012-10-15 | 2014-04-24 | Oncomed Pharmaceuticals, Inc. | Methods of treating ocular diseases |
| AU2013337811A1 (en) | 2012-10-31 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| US9931199B2 (en) * | 2014-05-05 | 2018-04-03 | Roberto Gustavo ALBERTAZZI | Methods and apparatus for treating keratoconus |
| MX382902B (es) | 2014-10-31 | 2025-03-13 | Oncomed Pharm Inc | Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer. |
| WO2017053705A1 (en) | 2015-09-23 | 2017-03-30 | Oncomed Pharmaceuticals, Inc. | Methods and compositions for treatment of cancer |
| WO2018094267A1 (en) * | 2016-11-17 | 2018-05-24 | Children's Medical Center Corporation | Novel methods to enhance microvascular engraftment of bioengineered and primary tissues |
| WO2023063842A1 (ru) | 2021-10-12 | 2023-04-20 | Общество с ограниченной ответственностью "Пальмира Биофарма" | Нуклеотидная последовательность, кодирующая слитый белок |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7306799B2 (en) * | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| WO2007028110A2 (en) * | 2005-09-01 | 2007-03-08 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| US20080014196A1 (en) * | 2006-06-06 | 2008-01-17 | Genentech, Inc. | Compositions and methods for modulating vascular development |
-
2007
- 2007-08-07 CA CA2660235A patent/CA2660235C/en active Active
- 2007-08-07 SI SI200731170T patent/SI2054082T1/sl unknown
- 2007-08-07 HR HRP20130271TT patent/HRP20130271T1/hr unknown
- 2007-08-07 ES ES07811137T patent/ES2398253T3/es active Active
- 2007-08-07 KR KR1020097004668A patent/KR101497355B1/ko active Active
- 2007-08-07 US US11/890,741 patent/US20080181893A1/en not_active Abandoned
- 2007-08-07 PL PL07811137T patent/PL2054082T3/pl unknown
- 2007-08-07 NZ NZ574794A patent/NZ574794A/en unknown
- 2007-08-07 PT PT78111374T patent/PT2054082E/pt unknown
- 2007-08-07 DK DK07811137.4T patent/DK2054082T3/da active
- 2007-08-07 MX MX2009000674A patent/MX2009000674A/es active IP Right Grant
- 2007-08-07 BR BRPI0716424A patent/BRPI0716424B8/pt active IP Right Grant
- 2007-08-07 MY MYPI20090335A patent/MY150092A/en unknown
- 2007-08-07 EP EP07811137A patent/EP2054082B1/en active Active
- 2007-08-07 CN CN200780029497.8A patent/CN101500605B/zh active Active
- 2007-08-07 RU RU2009107921/15A patent/RU2429876C2/ru active
- 2007-08-07 SG SG2011055829A patent/SG174033A1/en unknown
- 2007-08-07 ME MEP-31/09A patent/ME00591A/xx unknown
- 2007-08-07 WO PCT/US2007/017546 patent/WO2008019144A2/en not_active Ceased
- 2007-08-07 AU AU2007281916A patent/AU2007281916B2/en active Active
- 2007-08-07 UA UAA200902033A patent/UA95304C2/ru unknown
- 2007-08-07 RS RS20130078A patent/RS52685B/sr unknown
- 2007-08-07 JP JP2009523820A patent/JP5529536B2/ja active Active
-
2009
- 2009-01-15 ZA ZA2009/00337A patent/ZA200900337B/en unknown
- 2009-01-20 IL IL196612A patent/IL196612A/en active IP Right Grant
- 2009-02-03 TN TN2009000036A patent/TN2009000036A1/fr unknown
- 2009-02-05 SV SV2009003161A patent/SV2009003161A/es unknown
- 2009-02-06 GT GT200900029A patent/GT200900029A/es unknown
- 2009-02-20 CR CR10627A patent/CR10627A/es unknown
- 2009-02-26 MA MA31667A patent/MA30667B1/fr unknown
- 2009-03-04 NO NO20090984A patent/NO341857B1/no unknown
- 2009-03-05 CO CO09022898A patent/CO6150190A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20090984L (no) | Terapeutiske fremgangsmater for behandling av vaskulaere oyelidelser med DLL4-antagonister | |
| Bentov et al. | The effect of aging on the cutaneous microvasculature | |
| Nomoto et al. | Evaluation of radial optic neurotomy for central retinal vein occlusion by indocyanine green videoangiography and image analysis | |
| Wang et al. | Preclinical efficacy of human Albumin in subarachnoid hemorrhage | |
| Liang et al. | Ischemic preconditioning ameliorates spinal cord ischemia-reperfusion injury by triggering autoregulation | |
| Yamaji et al. | Evaluation of arteriovenous crossing sheathotomy for branch retinal vein occlusion by fluorescein videoangiography and image analysis | |
| Lin et al. | Target blood pressure for hypotensive resuscitation | |
| RU2421221C1 (ru) | Способ лечения критической ишемии нижних конечностей различного генеза | |
| ES2902838T3 (es) | El ácido glicólico protege contra los infartos | |
| Steigerwalt et al. | Nonarteritic anterior ischemic optic neuropathy treated with intravenous prostaglandin E1 and steroids | |
| Sohn et al. | Arteriovenous sheathotomy for persistent macular edema in branch retinal vein occlusion | |
| Uva et al. | The effect of timolol-dorzolamide and timolol-pilocarpine combinations on ocular blood flow in patients with glaucoma | |
| Froehler et al. | Angiographic investigation of orbital vascular variations in the rabbit and implications for endovascular intra-arterial chemotherapy models | |
| RU2306957C1 (ru) | Способ регионарной анестезии при операции ампутации нижних конечностей | |
| DOP2009000015A (es) | Uso de antagonistas de dll4 para tratar trastornos oculares vasculares | |
| CY1113840T1 (el) | Χρηση ανταγωνιστων d114 σε ισχαιμικη βλαβη ή αγγειακη ανεπαρκεια | |
| Delgado et al. | Endothelin‐1 effects on spontaneous oscillations in choroidal arterioles | |
| Bennet | Pegaptanib for the treatment of ischemic retinopathy in patients with diabetes and retinal vascular occlusive disorders | |
| Mohammad et al. | Evaluation of ketamine as an adjuvant to lidocaine in intravenous regional anesthesia for upper limb surgery | |
| Jablonka et al. | Comparing the effect of arginine vasopressin on ear and finger photoplethysmography | |
| RU2309737C1 (ru) | Способ индукции при продленной спинномозговой анестезии | |
| Minic et al. | Purinergic receptor antagonism: A viable strategy for the management of autonomic dysreflexia? | |
| Han | Mechanisms and Treatments for Reperfusion Injury of the Brain During Cardiac Arrest and Resuscitation | |
| Korchemkina et al. | Clinical case of resistant macular edema in a patient with diabetes | |
| Coetzee et al. | Calcium antagonist verapamil and reperfusion injury of the heart |